Tafolecimab
Trade name: SINTBILO
mAbexperimental
Clinical trial activity
14 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
8
Phase 3
6
Phase 4
1
Earliest trial started Nov 27, 2017 (NCT03366688)
Timeline
Indications
Approved for
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Small Cell · Phase 2
- Drugs, Investigational · Phase 3
- Healthy Volunteers · Phase 1
- Homozygous Familial Hypercholesterolemia · Phase 3
- Hypercholesterolemia · Phase 3
- Lipid Metabolism Disorders · Phase 2/Phase 3
- Lung Neoplasms · Phase 2
- Myocardial Infarction · Phase 4
- Pharmacological and Toxicological Phenomena · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Subtilisin · Phase 2/Phase 3
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594554 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07061535 | Phase 2 | Aug 1, 2025 | Innovent Biologics (Suzhou) Co. Ltd., Zhejiang University |
| NCT07014215 | Phase 2 | Jun 30, 2025 | Anhui Medical University |
| NCT06683131 | Phase 4 | Dec 1, 2024 | Peking University, Xuzhou Medical University |
| NCT06421298 | Phase 2 | May 17, 2024 | Capital Medical University |
| NCT06096909 | N/A | Nov 1, 2023 | Chinese Academy of Medical Sciences, Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05792917 | Phase 1 | Mar 6, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04709536 | Phase 3 | Feb 9, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04759534 | Phase 3 | Sep 10, 2020 | Innovent Biologics (Suzhou) Co. Ltd., Shenzhen University |
| NCT04289285 | Phase 3 | Apr 30, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04179669 | Phase 3 | Nov 30, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04948008 | Phase 2/Phase 3 (Phase 3) | Nov 5, 2019 | Shenzhen University |
| NCT04031742 | Phase 2/Phase 3 (Phase 3) | Aug 12, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT03815812 | Phase 2 | Mar 7, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT03366688 | Phase 1 | Nov 27, 2017 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 10 | 7 | 4 | 2017 |
| Shenzhen University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1